Fiche publication
Date publication
août 2025
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel
Tous les auteurs :
Poitureau S, Le Deley MC, Brahmi M, Bompas E, Kurtz JE, Nannini S, Perrin C, Lebellec L, Ryckewaert T, Ould-Ammar R, Leguillette C, Blay JY, Penel N
Lien Pubmed
Résumé
Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent. The need to maintain a high relative dose intensity (RDI) is not clearly established in this clinical setting.
Mots clés
dose reduction, relative dose intensity, soft tissue sarcoma, toxicity, trabectedin
Référence
Cancer Med. 2025 08;14(16):e71131
